Aerpio Pharmaceuticals, Inc.
If you purchased Aerpio Pharmaceuticals, Inc. securities and would like to join the action, please click "Join This Action" below.
AERPIO MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE MERGER OF AERPIO PHARMACEUTICALS, INC. IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM – ARPO
May 18, 2021.
New York, New York—Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Aerpio Pharmaceuticals, Inc. (NASDAQ: ARPO) and Aadi Bioscience, Inc. is fair to Aerpio shareholders. Under the terms of the merger agreement, shareholders of Aadi will receive shares of newly issued Aerpio common stock. On a pro forma basis, shareholders of Aerpio will own approximately 33.2% of the combined company upon the closing of the merger, prior to the additional PIPE financing transaction. Following the closing of the concurrent PIPE financing, Aerpio shareholders will own approximately 14.7% of the combined company.
The investigation concerns whether Aerpio and its board violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Aerpio shareholders; and (2) disclose all material information necessary for Aerpio shareholders to adequately assess and value the merger consideration. On behalf of Aerpio shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.